Compare · CYPH vs NVO
CYPH vs NVO
Side-by-side comparison of Cypherpunk Technologies Inc. (CYPH) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CYPH and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 1219.1x CYPH ($176.7M).
- Over the past year, CYPH is up 470.6% and NVO is down 12.1% - CYPH leads by 482.7 points.
- CYPH has been more active in the news (10 items in the past 4 weeks vs 9 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 1 for CYPH).
- Company
- Cypherpunk Technologies Inc.
- Novo Nordisk A/S
- Price
- $1.66-0.60%
- $48.65+3.65%
- Market cap
- $176.7M
- $215.46B
- 1M return
- +165.30%
- -2.08%
- 1Y return
- +470.64%
- -12.07%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 10
- 9
- Recent ratings
- 1
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CYPH
- SEC Form 4 filed by Head of Mining Zhang Kevin to satisfy withholding obligation
- New insider Zhang Kevin claimed ownership of 330,904 shares (SEC Form 3)
- Chief Investment Officer Mcevoy William Patrick Iii exercised 16,570,852 in-the-money shares at a strike of $0.00 (SEC Form 4)
- Large owner Winklevoss Capital Fund, Llc exercised 16,570,852 in-the-money shares at a strike of $0.00 (SEC Form 4)
- Cypherpunk Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
- Cypherpunk Technologies Launches World's Largest Zcash Mining Fleet
- SEC Form 10-Q filed by Cypherpunk Technologies Inc.
- Cypherpunk Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Cypherpunk Technologies Reports Second Quarter 2026 Financial Results
- Leap Therapeutics Announces Publication of DeFianCe Study Results in Clinical Cancer Research
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S